MedTrace Logo

Nasal Administration of Sufentanil+Ketamine for Procedure-related Pain in Children

NCT01047241 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2014-09-17

Study results available
· View outcomes & findings →

Summary

The aim of the study is to investigate the absorption and clinical effect of nasal administration of an analgesic nasal spray containing sufentanil+ketamine for pain related to medical procedures in hospitalized children.

Conditions

Interventions

DRUG

Intranasal sufentanil/ketamine

Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose

Sponsors & Collaborators

  • Rigshospitalet, Denmark

    collaborator OTHER

  • Danish University of Pharmaceutical Sciences

    lead OTHER

Principal Investigators

  • Steen W Henneberg, MD DMSc · Rigshospitalet, Denmark

  • Kjeld Schmiegelow, MD DMSc · Copenhagen University Hospital Righospitalet

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01047241 on ClinicalTrials.gov